BIOGEN INC. is 3.1x more valuable than Krystal Biotech, Inc. by market capitalization ($28.68 B vs $9.21 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KRYS | BIIB |
|---|---|---|
| Market cap | $9.21 B | $28.68 B |
| US-listed rank | #989 | #476 |
| Revenue (latest FY) | $389.13M | $9.89B |
| Net income (latest FY) | $204.83M | $1.29B |
| Net margin | 52.6% | 13.1% |
| P/E (trailing FY) | 45.0 | 22.2 |
| SEC filings | 483 | 2,690 |
BIOGEN INC. is 3.1x more valuable than Krystal Biotech, Inc. by market capitalization ($28.68 B vs $9.21 B).
In their latest fiscal years, Krystal Biotech, Inc. reported $389.13M in revenue while BIOGEN INC. reported $9.89B.
Full pages: Krystal Biotech, Inc. and BIOGEN INC., or browse the full rankings.